Abstract 2128P
Background
Exercise (EX) is associated with a reduction in mortality and recurrence risk in patients (pts) with cancer and may help pts cope with treatment side effects and improve their quality of life. This study aims to explore the role of oncologists in promoting exercise in the oncological context.
Methods
A self-administered, anonymous questionnaire was proposed to pts visiting the outpatients’ facilities at the Oncology Unit of Verona Hospital. The questionnaire assessed demographic, health, and EX parameters. EX variables, drawn from a prior study, included: the level evaluated with Godin’s Leisure Time Exercise Questionnaire and information regarding: whether EX was discussed; whether oncologists assess, advise, reinforce, and refer (AARR process) pts effort to exercising; and whether pts preferred that EX be discussed. Descriptive statistic, presented as mean, frequencies, and percentages, was applied.
Results
Overall, 202 pts completed the survey (76% response rate). The most frequent tumor types were upper gastrointestinal (45%) and breast (19%). Only 9% of pts were sufficiently active. Regarding the actual EX discussion, 29% of pts reported that their oncologist started a discussion about EX, 12% initiated the discussion themselves, and 60% referred that the issue was not considered. Concerning the AARR process, 26% of pts declared that their oncologists assessed their EX level, 14% and 33% received advice or reinforcement to increase their EX, respectively, and 9% were referred to an appropriate EX service. On the other hand, the items related to the preferred modality of EX discussion showed that 69% of pts thought that oncologists should initiate an EX-discussion, 3% that only pts should start the discussion, and 23% thought that EX should not be discussed.
Conclusions
Our preliminary results show that most pts are insufficiently active, and the majority stated that they did not discuss EX. Nevertheless, most pts would prefer that oncologists initiate a discussion about EX. According to these findings, strategies to support clinicians in promoting EX to their pts should be developed. Further pts’ enrollment is currently ongoing and a more updated analysis will be available for presentation at the ESMO Congress.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2076P - Topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy: An exploratory subgroup analysis of the D-ToRCH phase III trial
Presenter: Akhil Santhosh
Session: Poster session 06
2077P - A randomized, placebo-controlled trial assessing the efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, B1, B2, B6, E, Mg, Zn and a fatty acid for 6 months in the management of chemotherapy induced neuropathic pain
Presenter: Triantafylos Didangelos
Session: Poster session 06
2078P - Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan
Presenter: Florian Scotté
Session: Poster session 06
2079P - Naloxegol for the treatment of opioid-induced constipation in patients with cancer pain: A pooled analysis of real-world studies (NALOPOOL)
Presenter: Maria del Carmen Beato Zambrano
Session: Poster session 06
2080P - Incidence and risks of intravenous chemotherapy-induced neutropenia (ICIN) in oncology: A multicenter retrospective cohort study on real-life data
Presenter: Olivia Rohr
Session: Poster session 06
2081P - The therapeutic effect of anti-inflammatory tripeptide cream on hand-foot syndrome related to anticancer drugs: A prospective, randomized, placebo-controlled pilot trial
Presenter: Yaewon Yang
Session: Poster session 06
2082P - TASMAN: An international survey on the knowledge, aTtitudes and clinical pAtternsS of use of Medical Cannabis for caNcer care
Presenter: Marco Filetti
Session: Poster session 06
2083P - Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort
Presenter: Rocío Martín Lozano
Session: Poster session 06
2084P - Cardiovascular (CV) mortality among metastatic cancer patients: A retrospective cohort study
Presenter: Irbaz Riaz
Session: Poster session 06